Compare ONC & WCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ONC | WCN |
|---|---|---|
| Founded | 2010 | 1997 |
| Country | Switzerland | Canada |
| Employees | 12000 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Power Generation |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.6B | 41.9B |
| IPO Year | 2015 | 2005 |
| Metric | ONC | WCN |
|---|---|---|
| Price | $376.01 | $167.10 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 19 |
| Target Price | ★ $385.10 | $204.21 |
| AVG Volume (30 Days) | 359.1K | ★ 1.1M |
| Earning Date | 05-06-2026 | 04-22-2026 |
| Dividend Yield | N/A | ★ 0.85% |
| EPS Growth | ★ 140.43 | 74.48 |
| EPS | 0.31 | ★ 2.02 |
| Revenue | $238,387,000.00 | ★ $9,466,915,000.00 |
| Revenue This Year | $723.76 | $6.14 |
| Revenue Next Year | $15.04 | $6.18 |
| P/E Ratio | $1,214.10 | ★ $82.25 |
| Revenue Growth | ★ 22179.16 | 6.14 |
| 52 Week Low | $253.95 | $146.89 |
| 52 Week High | $385.22 | $185.33 |
| Indicator | ONC | WCN |
|---|---|---|
| Relative Strength Index (RSI) | 69.42 | 52.12 |
| Support Level | $325.47 | $167.28 |
| Resistance Level | $385.22 | $173.00 |
| Average True Range (ATR) | 7.78 | 2.73 |
| MACD | 1.00 | 0.17 |
| Stochastic Oscillator | 89.03 | 62.28 |
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
Waste Connections is a North American waste management company focused on integrated waste collection services. The firm primarily focuses on residential, commercial, municipal, and industrial waste collection, with a secondary market focus on rural areas. With 113 landfills and 222 transfer stations as of 2024, it is the third-largest waste management company by revenue. Revenue is split among six operating segments: Western, Southern, Eastern, Central, Canada, and Midsouth.